Akebia Therapeutics, Inc. (AKBA) Social Stream



Akebia Therapeutics, Inc. (AKBA): $1.07

0.01 (+0.94%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add AKBA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#59 of 345

in industry

AKEBIA THERAPEUTICS INC (AKBA) Price Targets From Analysts

Use the tables below to see what analysts covering AKEBIA THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-05 4 $8 $2.75 $5.937 $0.923 543.23%
2022-01-28 2 $10 $6 $8 $0.923 766.74%
2022-03-02 3 $10 $6 $8 $0.923 766.74%
2022-03-08 4 $10 $6 $8 $0.923 766.74%
2022-03-31 7 $2 $2 $2 $0.923 116.68%
2022-05-10 7 $2 $1 $1.75 $0.923 89.6%
2022-05-16 6 $2 $1.25 $1.75 $0.923 89.6%
2022-06-06 7 $2 $1 $1.562 $0.923 69.23%
2023-03-10 2 $2 $1.25 $1.625 $0.923 76.06%
2023-04-26 2 $2 $2 $2 $0.923 116.68%
2023-05-26 3 $2 $2 $2 $0.923 116.68%
2023-07-24 3 $4 $2 $3 $0.923 225.03%
2023-08-25 3 $4 $2 $3 $0.923 225.03%
2023-11-09 3 $4 $3.75 $3.875 $0.923 319.83%

The Trend in the Analyst Price Target


Over the past 33 months, AKBA's average price target has gone down $3.12.

AKBA reports an average of 165.44% for its upside potential over the past 35 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-10 2 2 1.25 1.625 0.799 103.38%
2023-05-31 3 4 2.00 3.000 1.040 188.46%
2023-08-25 3 4 2.00 3.000 1.150 160.87%
2023-08-28 3 4 3.75 3.875 1.380 180.8%
2023-11-09 3 4 3.75 3.875 0.910 325.82%

AKBA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.67 2 0 1 0 0 3

The Trend in the Broker Recommendations


AKBA's average broker recommendation rating improved by 1.62 over the prior 17 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, AKEBIA THERAPEUTICS INC's average analyst price target is greater than 37.83% of them.
  • AKEBIA THERAPEUTICS INC's number of analysts covering the stock is greater than 242.33% of all US stocks.
  • AKEBIA THERAPEUTICS INC's variance in analysts' estimates is lower than -317.68% of Pharmaceutical Products stocks.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, AKEBIA THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 701.92% of them.

Stocks similar to AKEBIA THERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EGRX, CPRX, and LXRX.

Is AKBA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!